Financial Data and Key Metrics Changes - ATS reported record revenues of $792 million in Q4, an 8% increase from the previous year, with full-year revenues up 18% [8][19] - Adjusted earnings from operations for Q4 were $96 million, with full-year adjusted earnings at $398 million, a 16% increase compared to fiscal '23 [8][20] - The order bookings for Q4 were $791 million, a 7.3% increase year-over-year, with full-year bookings totaling $2.9 billion [7][18] Business Line Data and Key Metrics Changes - Life Sciences saw a backlog of $871 million, up 14% year-over-year, driven by demand for autoinjector assembly and automated pharmacy solutions [8][9] - Transportation backlog was $425 million, reflecting ongoing execution of large programs, but with expected pressure on EV revenues [9][10] - Food & Beverage bookings were strong in Q4, with an ending backlog of $230 million, supported by seasonal variations [10][11] Market Data and Key Metrics Changes - The Life Sciences market remains robust, with a strong opportunity funnel driven by increased demand for GLP-1 drugs and wearable devices [9][15] - The Transportation market is experiencing short-term uncertainty, with smaller opportunities in the near term compared to previous years [10][18] - The Energy market is focused on refurbishing existing nuclear reactors, with new projects being approved [11] Company Strategy and Development Direction - ATS is advancing its value creation strategy through acquisitions, having completed four in fiscal '24, including the recent acquisition of Paxiom [6][14] - The company is committed to innovation, increasing its patent portfolio by nearly 10% over the last year [6][7] - ATS is focused on driving improvements through its ABM culture, emphasizing continuous improvement and operational efficiency [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to offset expected lower revenues from EV with growth in other markets, particularly Life Sciences [20][78] - The backlog remains strong at $1.8 billion, providing good revenue visibility for fiscal '25 [8][24] - Management noted improvements in supply chain lead times and ongoing efforts to manage material cost pressures [21][22] Other Important Information - ATS has been active in its share buyback program, repurchasing over 1 million shares for $45 million [7][24] - The company incurred $6.6 million in restructuring costs in Q4, totaling $22.8 million for the full year, aimed at cost reductions to support growth [22][23] - ATS was recognized as one of Southwestern Ontario's Top Employers for 2024, highlighting its commitment to employee engagement [16] Q&A Session Summary Question: Impact of EV program reduction - Management confirmed that customers are responsible for compensating ATS up until the point of work cancellation, and they expect to recover working capital from the cancellation [30] Question: Potential further reductions in EV demand - Management does not expect further cancellations, noting that the descoped portion was in the early design phase [32] Question: Working capital concerns - Management indicated that milestone payments are expected to normalize working capital levels in the upcoming quarters [34] Question: Revenue outlook excluding EV - Management clarified that the exclusion of EV from revenue expectations is due to timing uncertainty, but they remain optimistic about growth in other areas [38] Question: Autoinjector revenue ramp - Management expects autoinjector revenues to increase from low single-digits to high single-digits over the next several years [45] Question: Free cash flow expectations - Management indicated that working capital impacts from EV will improve as milestones are reached in the second half of the fiscal year [48] Question: Adjusted EBIT margin target - Management reaffirmed the target for a 15% adjusted EBIT margin, emphasizing ongoing initiatives to drive efficiency [50] Question: Backlog changes - Management explained that the decline in backlog was primarily due to the EV cancellation, along with some normal course scope changes [66] Question: 2025 sales outlook - Management indicated that they expect to offset declines in EV sales with growth in other markets, particularly Life Sciences [78]

ATS (ATS) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 17.07%. A quarter ago, it was expected that this automation services provider would post earnings of $0.48 per share when it actually produced earnings of $0.48, delivering no surprise.Over the last four quarters, the company h ...

THOUSAND OAKS, Calif., May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner, executive vice presiden ...

Group 1 - ATS Corporation will participate in the Raymond James 45th Annual Institutional Investors Conference on March 6, 2024, with CEO Andrew Hider and CFO Ryan McLeod attending [1] - A fireside chat is scheduled for 11:00 a.m. (ET) during the conference, and a live webcast will be available on the Investor Relations site [1] - Management will also hold institutional investor meetings at the conference, which can be arranged through Raymond James representatives [1] Group 2 - ATS Corporation is a leading automation solutions provider, serving various industries including life sciences, transportation, food & beverage, consumer products, and energy [2] - The company was founded in 1978 and employs over 7,000 people across more than 65 manufacturing facilities and over 85 offices globally [2] - ATS's common shares are traded on the Toronto Stock Exchange and NYSE under the symbol ATS [2]

Group 1 - ATS Corporation will participate in the Barclays Industrials Select Conference in Miami, FL on February 22, 2024, with CEO Andrew Hider and CFO Ryan McLeod attending [1] - Management will host institutional investor meetings at the Conference, which can be arranged through Barclays representatives [1] Group 2 - ATS Corporation is a leading automation solutions provider, serving many successful global companies [2] - The company specializes in custom automation, repeat automation, automation products, and value-added solutions, including pre-automation and after-sales services [2] - ATS operates in various markets such as life sciences, transportation, food & beverage, consumer products, and energy [2] - Founded in 1978, ATS employs over 7,000 people across more than 65 manufacturing facilities and over 85 offices worldwide [2] - The company's shares are traded on the Toronto Stock Exchange and NYSE under the symbol ATS [2]

Group 1 - ATS Corporation will participate in the Citi Global Industrial Tech and Mobility Conference on February 21, 2024, with CEO Andrew Hider and CFO Ryan McLeod attending [1] - A fireside chat is scheduled for 10:30 a.m. (ET) during the conference, and a webcast link will be available on the Investor Relations site [1] - Management will also host institutional investor meetings at the conference, which can be arranged through Citi representatives or by contacting ATS directly [1] Group 2 - ATS Corporation is a leading automation solutions provider, serving many successful global companies [2] - The company specializes in custom automation, repeat automation, and value-added solutions across various sectors, including life sciences, transportation, food & beverage, consumer products, and energy [2] - Founded in 1978, ATS employs over 7,000 people and operates more than 65 manufacturing facilities and over 85 offices worldwide [2]

ATS Corporation (NYSE:ATS) Q3 2024 Earnings Conference Call February 7, 2024 8:30 AM ET Company Participants David Galison - Head of Investor Relations Andrew Hider - Chief Executive Officer Ryan McLeod - Chief Financial Officer Conference Call Participants Patrick Sullivan - TD Cowen David Ocampo - Cormark Securities Inc. Michael Doumet - Scotiabank Patrick Baumann - JPMorgan Chase & Co. Michael Glen - Raymond James & Associates, Inc. Justin Keywood - Stifel GMP Maxim Sytchev - National Bank Financial Saba ...

Financial Performance - Q3 2024 revenues increased by approximately 16% year-over-year to $752 million[8, 11] - Q3 2024 adjusted earnings from operations increased by approximately 17% year-over-year to $1012 million, with a 135% adjusted earnings from operations margin, up 13 bps year-over-year[8, 11] - Q3 2024 EBITDA increased by $298 million to $1137 million, a 355% increase year-over-year[11] - Q3 2024 adjusted EBITDA increased by $186 million to $1193 million, a 185% increase year-over-year[11] - Q3 2024 net income increased by $18 million to $472 million, a 616% increase year-over-year[11] - Q3 2024 basic earnings per share increased by $016 to $048, a 50% increase year-over-year[11] - Q3 2024 adjusted basic earnings per share increased by $009 to $065, a 161% increase year-over-year[11] Order and Backlog - Q3 2024 order bookings decreased by approximately 32% year-over-year to $668 million, which included $221 million USD EV Order Bookings (approximately $3002 million CAD)[8] - Order backlog of $1907 million provides good revenue visibility[8] - Estimated Q4 F24 order backlog-to-revenue conversion is 36% to 39%[11, 13] Market Outlook - Life Sciences order backlog is $875 million, with a strong funnel focused on strategic areas[9] - Transportation order backlog is $564 million, including approximately $200 million on delayed projects, with strong funnel and long-term fundamentals[9]

ATS (ATS) came out with quarterly earnings of $0.48 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this automation services provider would post earnings of $0.48 per share when it actually produced earnings of $0.46, delivering a surprise of -4.17%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.ATS, which belongs to t ...

The market expects ATS (ATS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Feb ...